Evidence map›Paper›PMID 41170715›Full record

ArticleFuture oncology (London, England)2025

Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives.

Ruhee Jain, Amanda Ribbands, Jake Butcher, Sophie Barlow, Jacob Skilling, Andrea Stevens, Katie Pascoe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ruhee JainMarket Access, Johnson & Johnson, Raritan, NJ, USA.
Amanda RibbandsOncology, Adelphi Real World, Bollington, UK.
Jake ButcherOncology, Adelphi Real World, Bollington, UK.
Sophie BarlowStatistics & Data Analytics, Adelphi Real World, Bollington, UK.
Jacob SkillingOncology, Adelphi Real World, Bollington, UK.
Andrea StevensPrecision Medicine Access, Johnson & Johnson, Raritan, NJ, USA.
Katie PascoeMarket Access, Johnson & Johnson, High Wycombe, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo understand how genetic (homologous recombination repair [HRR], including BReast CAncer [BRCA]) testing is being embedded in clinical practice and identify testing challenges given global approvals of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) for metastatic prostate cancer (mPCa).

methodsData from two Adelphi Real World Prostate Cancer Disease Specific Programmes™ (DSPs; 2020 and 11/2022-7/2023) were analyzed and compared using appropriate bivariate tests.

resultsGenetic testing was performed among 45% (855/1899) of patients with mPCa (castration-sensitive [mCSPC]: 36%; castration-resistant [mCRPC]: 49%; HRR genes: 43% [34%; 47%];

conclusionsUnderstanding physicians' and patients' experiences with, and challenges surrounding, genetic testing for PCa may facilitate better clinical-management interactions.

Indexed as

Genetic TestingProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedHumansMaleMiddle AgedMutationNeoplasm MetastasisPhysiciansPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerase InhibitorsBRCADDRgenetic mutationhomologous recombination repairMetastatic prostate cancerPARP inhibitorreal worldtesting

Identifiers

PMID41170715
PMCPMC12622337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.